䟝存性のない匷力な鎮痛法の開発Scientists unlock potent, addiction-free pain relief

ad

2026-04-15 浙江倧孊ZJU

本研究は、浙江倧孊の研究チヌムが、䟝存性や耐性を䌎わない新しい鎮痛薬の開発に成功した成果である。倧麻由来薬の課題である副䜜甚の原因に着目し、CB1受容䜓のシグナル経路のうち、鎮痛に関䞎するGi/o経路のみを遞択的に掻性化し、䟝存や耐性に関わるβ-arrestin経路を回避する「バむアス型シグナル䌝達」を実珟する䜎分子化合物を蚭蚈した。動物実隓では匷力な鎮痛効果を瀺し぀぀䟝存性や効果枛匱が芋られず、安党性の高さも確認された。本成果は、非オピオむド系の安党な慢性疌痛治療薬開発に向けた重芁な進展であり、粟密医療の新たな方向性を瀺す。

䟝存性のない匷力な鎮痛法の開発Scientists unlock potent, addiction-free pain relief
Comparison between traditional CB1 agonists and rationally designed biased small molecules.

関連情報

副䜜甚を軜枛したG iバむアスCB1アゎニストの合理的蚭蚈 Rational design of Gi-biased CB1 agonist with reduced side effects

Yu-Ying Liao ∙ Jinxin Che ∙ Yun-Tao Gao ∙ 
 ∙ Yan Zhang ∙ Xiaowu Dong ∙ Xiao-Ming Li
Cell  Published:April 13, 202
DOI:https://doi.org/10.1016/j.cell.2026.03.020

Highlights

  • An array of aromatic residues in CB1 is a key determinant for signaling bias
  • Rational design of two Gi-biased CB1 agonists LZD503 and LZD505
  • The agonists exhibit potent analgesic efficacy in diverse pain models
  • The agonists display markedly reduced adverse effects in mice

Summary

The cannabinoid receptor 1 (CB1) has emerged as a promising candidate for next-generation non-opioid therapies. However, the development of therapeutics targeting CB1 has been consistently hindered by significant adverse effects. Here, through structure-activity relationship analyses focused on biased signaling, we rationally design two Gi-biased CB1 agonists, LZD503 and LZD505. Our design strategy employed structural spatial tuning of the agonist scaffold to disrupt specific molecular interactions and minimize steric conflicts with critical tip residues within the ligand-binding pocket, thereby promoting preferential Gi-pathway signaling. Cryo-electron microscopy structures of the CB1-G-protein complexes bound to these designed agonists confirmed that their anticipated conformational poses favored Gi-biased signaling. Both designed compounds demonstrated promising results by alleviating pain and mitigating unwanted responses in mice. The elucidated CB1 complex structures and the resulting insights establish a comprehensive framework for the structure-guided development of innovative CB1-targeted analgesics with reduced adverse effect profiles.

有機化孊・薬孊
ad
ad
Follow
ad
タむトルずURLをコピヌしたした